Emyria Ltd's (ASX:EMD) Michael Winlo speaks to Proactive's Andrew Scott following the news they've entered into a partnership with Cann Group Limited (ASX:CAN) (OTCMKTS:CNGGF) (FRA:CVJ) to accelerate registration of a unique, low-dose, CBD-only capsule with Australia’s Therapeutic Goods Administration (TGA). Under the agreement, Emyria’s EMD-003 drug development program will use Cann Group’s proprietary Gelpell microsphere technology to seek a Schedule 3 registration for treating unmet needs in mental health.
Emyria hails partnership with Cann Group to accelerate registration of unique CBD product
